Palonosetron intravenous - Helsinn Healthcare
Alternative Names: 2-QHBIQO; Aloxi Injection; Nuowei; ONICIT; Onicit; Palonosetron hydrochloride; Paloxi; RS-25259; RS-25259-197; RS-42358-197Latest Information Update: 05 Nov 2023
At a glance
- Originator Roche Palo Alto LLC
- Developer Helsinn; HK inno.N; Taiho Pharmaceutical
- Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
Most Recent Events
- 24 Jan 2023 Immedica in-licenses palonosetron from Helsinn for commercialization in Switzerland, Belgium and Liechtenstein
- 02 Aug 2022 Vifor Pharma has been acquired by CSL and renamed to CSL Vifor
- 01 Oct 2021 Marketing and distribution rights for Palonosetron hydrochloride licensed to Shanghai Fosun Pharmaceutical in Mainland China, Hong Kong SAR and Macau SAR